First-line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48-week results
Open Access
- 1 July 2002
- journal article
- clinical trial
- Published by Wiley in HIV Medicine
- Vol. 3 (4) , 277-282
- https://doi.org/10.1046/j.1468-1293.2002.00123.x
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Pharmacokinetic Profile and Tolerability of Indinavir-Ritonavir Combinations in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 2001
- A Retrospective, Cohort-Based Survey of Patients Using Twice-Daily Indinavir + Ritonavir Combinations: Pharmacokinetics, Safety, and EfficacyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Adverse effects of antiretroviral therapyThe Lancet, 2000
- Changes in renal function associated with indinavirAIDS, 1998
- Pharmacokinetic Interaction between Ritonavir and Indinavir in Healthy VolunteersAntimicrobial Agents and Chemotherapy, 1998
- Randomised placebo-controlled trial of ritonavir in advanced HIV-1 diseaseThe Lancet, 1998
- Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral TherapyNew England Journal of Medicine, 1997
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997
- Ordered accumulation of mutations in HIV protease confers resistance to ritonavirNature Medicine, 1996
- Treatment of Human Immunodeficiency Virus Infection with Saquinavir, Zidovudine, and ZalcitabineNew England Journal of Medicine, 1996